In vitro and in vivo antitumor activity of a novel chlorin derivative for photodynamic therapy

Abstract

In presented paper, a new chlorin derivative 5,10,15,20-tetrakis[(5-N-morpholino)pentyl] chlorin (TMC) was investigated as a photosensitizer in photodynamic therapy (PDT). Cellular uptake, cytotoxicity, intracellular location, biodistribution and antitumor effects were studied using human esophageal cancer cells (Eca-109) and human cervical cancer cells (Hela) in vitro and an esophageal cancer model in BALB/c nude mice. Cellular uptake and biodistribution of TMC were measured by fluorescence spectrophotometer. Cytotoxicity of TMC against Eca-109 and Hela cells was determined by MTT assay. The intracellular location of TMC was detected with a confocal microscopy. It was showed that TMC could rapidly accumulate in tumor cells and localize in cytoplasm. TMC was found to be low-toxic in dark but extensively photosensitive in vitro. A fast clearance rate of TMC was observed in Eca-109-bearing mice. In particular, TMC could significantly inhibit the tumor growth and exhibit a notable antitumor efficacy for PDT in vivo.

Devices and Methods for Dosimetry of Personalized Photodynamic Therapy of Tumors: A Review on Recent Trends

“…Photodynamic therapy (PDT) is one of the prospective methods for the treatment of precancerous and cancerous diseases, which already today shows high antitumor and antiviral efficacy. PDT works on the principle of light-induced activation of photosensitizers (PSs) and leads to cancer cell death mediated by reactive oxygen species (ROS), which ensures tumor growth cessation by triggering apoptosis and/or necrosis processes in the area of laser exposure, damage to blood vessels within the tumor that feed it and deliver oxygen, and has both local cytotoxic and systemic immunomodulatory effects [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16].…”